Table 2 Hazard ratio (HR) and corresponding 95% confidence interval (CI) for progression-free survival and overall survival in 163 patients with stage III–IV oropharyngeal squamous cell carcinoma

Sex

 Man

117

64

Reference

Reference

69

Reference

Reference

 Woman

46

26

1.03 (0.64–1.63)

1.05 (0.65–1.70)

29

1.20 (0.77–1.87)

1.28 (0.81–2.02)

Age (years)

 < 60

40

20

Reference

Reference

22

Reference

Reference

 60–69

57

26

1.00 (0.54–1.83)

1.06 (0.57–1.98)

31

1.11 (0.63–1.97)

1.18 (0.66–2.15)

 ≥ 70

66

44

1.91 (1.10–3.33)

1.47 (0.83–2.64)

45

1.80 (1.05–3.07)

1.54 (0.88–2.58)

T stage^c

 T1-T2

75

35

Reference

Reference

37

Reference

Reference

 T3-T4

88

55

1.74 (1.13–2.69)

1.42 (0.89–2.25)

61

1.76 (1.16–2.68)

1.32 (0.84–2.08)

N stage^c

 N0-N1

45

29

Reference

Reference

30

Reference

Reference

 N2

105

51

0.79 (0.50–1.26)

1.20 (0.71–2.02)

58

0.86 (0.55–1.34)

1.13 (0.69–1.85)

 N3

13

10

2.29 (1.10–4.78)

2.87 (1.34–6.14)

10

2.29 (1.10–4.73)

2.65 (1.26–5.59)

HPV-status

 Negative

110

76

Reference

Reference

82

Reference

Reference

 Positive

46

13

0.30 (0.16–0.54)

0.43 (0.23–0.81)

14

0.29 (0.16–0.51)

0.39 (0.21–0.72)

Surgery

 No

73

40

Reference

43

Reference

 Yes

90

50

1.17 (0.75–1.82)

55

1.08 (0.70–1.65)

LINE-1 methylation

 ≥ 55%

80

34

Reference

Reference

40

Reference

Reference

 35–54%

48

28

1.60 (0.96–2.67)

1.46 (0.85–2.49)

29

1.41 (0.86–2.31)

1.25 (0.75–2.07)

 < 35%

35

28

3.21 (1.89–5.45)

2.76 (1.48–5.12)

29

3.19 (1.92–5.30)

2.39 (1.35–4.24)